C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I by unknown
C3b  COVALENTLY  BOUND  TO  IgG  DEMONSTRATES 
A  REDUCED  RATE  OF  INACTIVATION  BY 
FACTORS  H  AND  I 
BY  LOUIS F. FRIES,  THELMA A. GAITHER,  CARL H. HAMMER,  AND 
MICHAEL M. FRANK 
From the Laboratory of Clinical Investigation, National Institute of  Allergy and Infectious 
Diseases, National Institutes of Health, Bethesda, Maryland 20205 
Cleavage of C3 by the physiologic C3 convertases or by trypsin results in the 
generation of a metastable form of C3b bearing a reactive internal thioester (1). 
This thioester may undergo hydrolysis by solvent water molecules or may form 
ester  or  amide  linkages  with  suitable  acceptors.  Immunoglobulin  G  (IgG)  is 
reported  to  display  a  measurable  affinity  for  uncleaved  C3  (2)  and  has  been 
shown  to  be an  excellent  acceptor  of nascent  C3b  (3).  In  accord  with  these 
observations,  it  has  been  shown  that  complement  activation  by soluble,  IgG- 
bearing  immune  complexes  or  IgG-sensitized  bacteria  results  in  substantial 
deposition  of C3b  onto  antibody  molecules  (4-6).  More  recently,  "innocent 
bystander"  IgG  in  serum  has  been  shown  to  bind  C3b  when  complement  is 
activated by exogenous immune complexes (7). 
Several lines of evidence suggest that binding to IgG may alter the character- 
istics of C3b.  It  is  well  known  that  IgG  enhances  the  rate  and/or  extent  of 
alternative  pathway  activation  in  an  Fc  fragment-independent  manner  on  a 
variety of activating surfaces (8-10).  Further,  IgG can confer alternative  path- 
way-activating potential  on  nonactivating  surfaces (1 1,  12).  Sensitization  with 
IgG dramatically augments complement-mediated killing of some serum-resistant 
bacteria.  Recent  studies  by Joiner  et  al.  (13)  have  shown  that  this  effect  is 
obtained only if IgG is present on the bacterial surface at the time of initial C3b 
deposition; addition of IgG subsequent to this step has little influence (13). This 
effect, which persists even when overall C3b uptake on the subject organisms is 
equalized, suggests an intimate interaction between C3b and IgG on the bacterial 
surface that is not replaced by random juxtaposition of the molecules.  Using a 
fluid phase system, Medoff et al. (14) have shown that C3b which is incorporated 
into soluble, IgG-bearing immune complexes is largely insusceptible to the action 
of factors H  (/31H) and I  (C3b inactivator) at concentrations capable of quickly 
cleaving  free  C3b  or  C3b  bound  to  "nonactivating"  particles  such  as  sheep 
erythrocytes. 
In view of these data, we have undertaken studies of the influence of binding 
to IgG on the subsequent behavior of C3b. We report here that  small, hetero- 
dimeric complexes of C3b and IgG are readily formed in vitro by trypsin cleavage 
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of C3 in the presence of IgG. The majority of C3b a' chains in these complexes 
are covalently bound to  IgG heavy chains by a  hydroxylamine-sensitive bond. 
The  rate  of cleavage  of heavy chain-bound  a'  chains  by  factors  H  and  I  is 
markedly slowed relative to free C3b a' chains. This relative resistance to factor 
H- and factor I-mediated cleavage results solely from a  lowered affinity of the 
C3b covalently linked to  IgG (C3b-IgG)  for factor H.  Substitution for IgG of 
ceruloplasmin, a glycoprotein of similar size but no known immunologic activity, 
results in hetero-dimers that display no retardation of a' chain cleavage relative 
to free C3b, suggesting that this may be a special property of IgG. On a  weight 
basis,  C3b  complexed  to  IgG  is  shown  to  be  significantly more  effective  in 
alternative pathway consumption of serum C3 than is free fluid-phase C3b. 
Materials and Methods 
Protein Preparations.  C3 was prepared from normal human plasma by a modification 
of the  method of Hammer et  ai.  (15).  C3  was  functionally, immunochemically, and 
electrophoretically homogeneous. C3 was stored at 4°C in 0.15 M NaCI, 0.05 M phosphate 
buffer (pH 7.4), 0.01  M EDTA, and 25 uM p-nitrophenyl p'-guanidinobenzoate (NPGB) ~ 
(Sigma Chemical Co., St.  Louis, MO).  Freshly prepared C3 was used in trypsinization 
experiments after dialysis against phosphate-buffered isotonic saline, pH 7.4 (PBS). Stored 
C3  with diminished hemolytic activity was dialyzed against 0.1  M  NaCl and  0.02  M 
phosphate buffer (pH 7.0) with 0.002 M EDTA and subjected to ion exchange chroma- 
tography on QAE-Sephadex A-50 (Pharmacia Fine Chemicals, Piscataway,  NJ). As previ- 
ously described (16), application of a linear salt gradient of 0.1-0.25 M NaCI allowed the 
separation of a fraction enriched for hemolytically active C3 eluting at conductivities of 
11.0-12.5 mS/cm at 0 ° C. This material was concentrated, dialyzed against PBS, and used 
in the same manner as fresh C3. 
Factor H was prepared from human plasma as previously described (17). Factor I was 
purchased from Cordis Laboratories Inc., Miami, FL, in a  partially purified state and 
adsorbed twice with an anti-factor H  immunoabsorbent to deplete all factor H activity 
(17). 
Human IgG and ceruloplasmin were obtained as byproducts of C3 preparation (15). 
IgG was recovered from the drop-through fraction of plasma proteins applied to DEAE- 
Sephacel (Pharmacia Fine Chemicals) in 0.0032 M Na/K phosphate buffer (pH 7.4, 1.37 
m S/cm at 0 °C) containing protease inhibitors and EDTA as described (15). Application 
of a  salt  gradient  to  the  above  column  resulted  in  the  elution  of ceruioplasmin at 
conductivities of 7.7-8.0 mS/cm at 0 °C (15). Both IgG and ceruloplasmin were concen- 
trated and exchanged into 0.15  M  NaCI,  0.05  M phosphate buffer (pH  7.4),  0.01  M 
EDTA, and 0.02% sodium azide with the use ofa Minitan ultrafiltration system (Millipore 
Corp., Bedford, MA). IgG produced a single line in immunoelectrophoresis against goat 
anti-whole human serum (Cappel  Laboratories, Cochranville, PA), while ceruloplasmin 
demonstrated a trace contaminant (not seen on sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis [SDS-PAGE]),  which proved to be C9 by double diffusion analysis. 
Before use in C3b-binding experiments, IgG and ceruioplasmin were concentrated as 
needed by vacuum dialysis, exhaustively dialyzed against PBS, and centrifuged for 30 min 
at 48,000 g to remove large aggregates. 
Additional Reagents.  Lyophilized human serum albumin (HSA), gelatin, and soybean 
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trypsin inhibitor were obtained from Sigma Chemical Co. Trypsin-TPCK was obtained 
from Worthington Biochemical Corp., Freehold, NJ. Goat anti-human C3 antiserum was 
produced in our laboratory as previously described (15).  Goat anti-human ceruloplasmin 
and anti-HSA antisera were purchased from Atlantic Antibodies,  Westbrook, ME,  and 
staphylococcal protein  A-Sepharose 4B  was obtained  from Pharmacia Fine Chemicals. 
For  hemolytic  titrations  of C3,  sheep  erythrocytes were  obtained  from  the  National 
Institutes of Health animal facility. Guinea pig C1  was purchased from Cordis Laborato- 
ries,  Inc.; fimctionally pure  C2,  C4,  and  C5  through  C9  were prepared from human 
plasma by the methods of Hammer et al. (15). 
Radiolabeling of C3.  Purified human C3 was labeled with 1251 by either a modification 
of the method of Bolten and Hunter (18) or with N-chloro-benzenesulfonamide-derived 
polystyrene beads (Iodobeads; Pierce Chemical Co., Rockford, IL). In both cases, labeling 
was carried  out  at melting ice  bath  temperature.  Labeled C3  retained  70-80%  of its 
hemolytic activity and had specific activities of 0.136-0.329 ~Ci]#g C3. 
Preparation of C3b-IgG and C3b-Ceruloplasmin Complexes.  Human C3 labeled with ~25I 
(0.5-0.9 rag) was mixed with a 250-fold molar excess of IgG in 2-3 ml of PBS (final IgG 
concentration,  50-75  mg/ml) and  warmed  to  37°C.  An  amount  of freshly dissolved 
trypsin-TPCK equivalent to 2% of C3 by weight was added, and the mixture was incubated 
for 8  min at 37°C  (conditions were based on preliminary studies to determine optimal 
conditions for complete C3 conversion to C3b, without significant further fragmentation, 
in concentrated IgG). The cleavage was terminated by the addition of a fourfold weight 
excess of soybean trypsin inhibitor and a further 5 min incubation at 37°C. 2 M sodium 
acetate (pH 5.6) was then added to a  final concentration of 0.1  M, and solid NaCI was 
added  to achieve a  concentration  of 1 M.  NPGB (0.05  M  in dimethylformamide) was 
added to 25 uM, and the entire mixture was applied to a 1.5 ×  100 cm column containing 
Ultrogel AcA-34 (LKB Instruments, Inc., Gaithersburg,  MD) in  1 M  NaC1 and 0.1  M 
acetate (pH 5.6) with 25 uM NPGB and chromatographed in this buffer at a flow rate of 
10 ml/h. Heavy and light peaks of 1251 radioactivity were pooled as shown in Fig.  1 A. In 
•  125  initial  experiments  I-C3b-IgG hetero-dlmers were further enriched  from the  higher 
molecular weight pool by repeat AcA-34 chromatography, while the bulk of monomer 
IgG was removed from 125I-C3b in the lower molecular weight pool by immunoadsorption 
with Sepharose-coupled goat anti-human IgG. In later experiments, both pools from the 
AcA-34 column were concentrated and dialyzed against 0.09 M NaCI, 0.02 M phosphate 
buffer (pH 7.0), 0.002% gelatin, and 25 uM NPGB. The pools were applied separately to 
10-15-ml  columns containing  QAE-Sephadex  A-50  in  the  same starting buffer. After 
being washed with two column volumes of starting buffer, the columns were developed 
with linear salt gradients of 0.09-0.26 M NaCI in 0.02 M phosphate (pH 7.0) with NPGB 
and gelatin. Elution was carried out at 0.5 column volumes/h, and 0.25 column volume 
fractions were collected. Fig.  1  B depicts typical ion exchange profiles so obtained. Pool C 
represents  the  ~25I-C3b-IgG  hetero-dimer,  while pool D  contains  ~251-C3b. SDS-PAGE 
analysis  of the  various  pools,  followed  by  autoradiography,  is  shown  in  Fig.  2.  The 
purification of ~25I-C3b bound to ceruloplasmin was obtained by analogous methods, save 
that ceruloplasmin could be concentrated only to 30-40 mg/ml before significant precip- 
itation  occurred.  ~25I-C3b-ceruloplasmin hetero-dimers  were  enriched  from  the  initial 
reaction mixture by two sequential AcA-34 chromatography steps. ~25I-C3b and 125I-C3b 
conjugates were concentrated by vacuum dialysis  and stored in PBS with 0.02% sodium 
azide at 4 o  C. 
Assay of Cleavage by Factors H and I of Free and Bound C3b a ' Chains.  12~I-C3b,  which 
was either free, in covalent complex with  IgG, or in complex with ceruloplasmin, was 
diluted to the desired concentration in PBS containing 0.01  M EDTA and 25 ~M NPGB. 
A  baseline sample was immediately removed, added  to twice its volume of SDS-PAGE 
sample buffer containing 0.05  M Tris-HC1 (pH 6.7), 5% SDS,  0.01% bromphenol blue, 
25%  sucrose,  and  3%  2-mercaptoethanol,  and  heated  at  95°C  for  5  rain.  In  serum 
cleavage studies, the experimental mixture was prewarmed to 37 °C, and an appropriate 
amount of NHS pretreated with  0.01  M  EDTA and  25 #M  NPGB was added at time 
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mixed with sample buffer and heated as above. In dose-response experiments with factors 
H and I, mixtures of the l~SI-C3b species, purified factor H, and factor I in the desired 
concentrations in PBS with 0.01  M EDTA and 25 #M NPGB were assembled in a melting 
ice bath and transferred to a 37°C bath at time zero. After the desired time, two volumes 
of the above sample buffer were added to each specimen and the mixture heated as above. 
Specimens were subjected to SDS-PAGE by the method of Maizel (19) with 5, 7, or 4- 
8% gradient polyacrylamide slab gels in a model 220 vertical electrophoresis cell (Bio-Rad 
Laboratories, Richmond,  CA).  After being stained  with  Coomassie Blue,  the gels were 
dried.  Autoradiography was performed with the use of 18-24-h  exposures of DuPont 
Cronex 6-Plus x-ray film at -60°C in cassettes containing DuPont Cronex Lightning Plus 
intensifying screens.  Densitometric  scanning of autoradiographs  was carried  out  on  a 
spectrophotometer (DU-8; Beckman Instruments, Inc., Fullerton,  CA) with white light; 
peaks were integrated, and their area was expressed as a percentage of total for the lane. 
Cleavage of the various chains was monitored by plotting their diminution relative to the 
entire lane with time, with the percentage of the relevant chain taken at time zero as a 
100% value. 
Consumption of C3 from Serum by C3b Species.  ~2"~I-C3b  or '25I-C3b-IgG were diluted to 
desired concentrations in ice-cold veronal-buffered isotonic saline (VBS), pH 7.4, contain- 
ing 40 mg/ml of HSA and 2 mM MgCI2.4 vol of fresh normal human serum (NHS) were 
mixed  with  1  vol  of 0.01  M  MgCI2  and  0.05  M  EGTA  in  VBS  (Mg/EGTA-NHS). 
Sufficient Mg/EGTA-NHS to achieve a final serum dilution of 1:25  was then added on 
ice to tubes containing buffer alone or various dilutions of 1~I-C3b or 125I-C3b-IgG. One 
buffer tube was immediately treated with an equal  volume of ice-cold VBS containing 
0.02 M EDTA and held on ice. All other tubes were placed simultaneously into a  37°C 
bath and incubated for 30 min. After 30 rain, all tubes were returned to the ice bath and 
an equal volume of ice-cold VBS with 0.02 M EDTA was added to stop the reaction. In 
preliminary kinetic experiments, we found that C3 consumption by both C3b species had 
plateaued by 20 min at 37°C.  Residual hemolytic C3 titrations were then carried out on 
all  specimens  by standard  methods  (15).  C3  titers  were  based  on  the  mean  of four 
determinations on the linear portion of the dose-response curve. Results were expressed 
as percent consumption of hemolytic serum C3 relative to the buffer control not exposed 
to 37°C. 
Results 
Formation of 12sI-C3b-lgG.  12~I-C3b-IgG hetero-dimers were formed in small 
amounts by trypsinization of 125I-C3  in the presence of IgG at serum concentra- 
tions.  Increasing IgG input  to 60-70  mg/ml and  a  250-fold  molar excess over 
~25I-C3 resulted in routine incorporation of 50-60% of ~2~I-C3 radioactivity into 
high molecular weight forms, the majority of which were bound by staphylococcal 
protein A-Sepharose (Figs.  1, left, and 2).  12~I-C3b-IgG was separated from 125I- 
C3b  by  sequential  sieve and  anion  exchange  chromatography  as  described  in 
Materials and  Methods (Fig.  1,1eft and right).  SDS-PAGE of 125I-C3b revealed a 
single band  with an apparent  molecular weight of 190,000  under  nonreducing 
conditions (Fig.  2).  This band gave rise to a' and/3 chains upon reduction,  with 
apparent  molecular weights  of 114,000  and  76,000,  respectively.  ~25I-C3b-IgG 
contained a  major band of 330,000  mol wt and a minor band of the same size as 
12"~I-C3b on nonreduced gels. As shown in Fig.  2, reduction of this material with 
2% 2-mercaptoethanol revealed a' and/3 chains, as in 125I-C3b, as well as a major 
band at ~190,000  mol wt (consistent with c~' bound  to IgG heavy chains) and a 
minor band of 145,000  mol wt (consistent  with  a'  bound  to  IgG light chains). 
These  latter  bands  were  identical  to  those  adsorbed  from  the  initial  high 
molecular weight pool by staphylococcal protein  A  (Fig.  2).  ~25I-C3b-IgG pools 1644  RETARDED  INACTIVATION OF  C3b  BOUND  TO  IgG 
FIGURE  1.  Chromatographic separation of C3b-lgG from C3b. (Left) Chromatographic pro- 
file of l~Sl activity after AcA-34 sieve chromatography  of the 125I-C3b-IgGp~SI-C3b  mixture 
resulting from tryptic cleavage of ]25I-C3 in the presence of a 250-fold molar excess IgG. The 
column dimensions were  1.5 x  100 cm, and chromatography  was carried out in  1 M NaCI, 
0.1  M acetate (pH 5.6), and 25 #M NPGB. The flow rate was 10 ml/h, and fractions were 
0.01  column  volumes. SDS-PAGE of pool A (l~51-C3b-IgG fraction) and pool B (125I-C3b 
fraction) is shown in Fig. 2, d and g, respectively. (Right) Anion exchange chromatography  of 
pools A (upper profile) and B (lower profile) on 10-15-ml columns containing QAE-450. Pools 
were applied in 0.09 M NaCI, 0,02 M phosphate (pH 7.0), 0.002% gelatin, and 25 ~M NPGB 
to columns preequilibrated in the same buffer. Columns were washed with two column volumes 
of starting buffer and then developed with a linear 0.09-0.26 M NaCI gradient.  Elution was 
carried out at 0.5 column volumes/h, collecting 0.25 column volume fractions. ~*sI  activity is 
shown by a solid line, conductivity (mS/cm, 0°C) by a broken line. Free lgG appeared in the 
drop-through  fractions as shown. SDS-PAGE  of pool C (125I-C3b-lgG)  and pool D (1251-C3b) is 
shown in Fig. 2, a, b, h, and i. 
demonstrated persistent contamination with  5-10%  free 125I-C3b; this contami- 
nant  may  have  arisen  from  noncovalent  association  of  125I-C3b  with  IgG  or 
spontaneous  release  of ~zSI-C3b from the  covalent complex.  Both  mechanisms 
have been previously described (2, 20).  During prolonged storage at 4°C in PBS 
(pH  7.4),  o~'  chain  was  progressively  released  (without  apparent  proteolytic 
cleavage) from both heavy and light chain with an approximate half-life of 22 d 
(first-order rate constant of-0.0013/h).  The average ratio of 0t'-heavy chain to 
o~'-light chain  was  3.2:1  in  four  separate  preparations.  Treatment  of 12SI-C3b- 
IgG with  1 M hydroxylamine and  1% SDS (pH 1 1.0) for 15 min at 37°C resulted 
in virtually complete release of radioactivity into two bands identical with the c~' 
and/3 of free 1251-C3b  on reduced SDS-PAGE (data not shown). 
Inactivation  of  ~25I-C3b  and  l~I-C3b-IgG  by  Serum.  To  assess  the  relative 
susceptibility of free C3b and C3b bound to IgG to inactivation by factors H  and 
I, we studied the kinetics of cleavage of 125I-labeled a' chains and 12~I-labeled 0J- 
heavy chains  in  the  presence  of dilute  serum.  5  /~g/ml  of 125I-C3b,  which  was 
free  or  bound  to  IgG, was  treated  with  1:50  NHS  in  PBS  containing  0.01  M 
EDTA and 25 #M  NPGB, as described in Materials and Methods.  Aliquots were FRIES  ET  AL.  1645 
FIGURE 2.  SDS-PAGE and autoradiography  of ]~I-C3b-lgG and IBI-C3b pools. SDS-PAGE 
on 4-8% polyacrylamide gradient gel. (a) 125I-C3b-lgG (pool C), nonreduced.  (b) 125I-C3b 
(pool D), nonreduced.  (c) I~I-C3, reduced. (d) High molecular weight pool after AcA-34 (pool 
A), reduced. (e) Staphylococcal protein A-binding material eluted from protein A-Sepharose 
after immunoabsorption of pool A; reduced. (f) Nonadsorbed material after immunoabsorp- 
tion of pool A with protein A-Sepharose; reduced. (g) Low molecular weight pool after AcA- 
34  (pool B);  reduced.  (h)  125I-C3b-IgG  (pool C),  reduced.  (i)  1~sI-C3b (pool  D),  reduced. 
Standards are shown × 10  s. 
125  125  FIGURE 3.  Serum inactivation of  I-C3b-IgG and  I-C3b. SDS-PAGE on 7% polyacryl- 
125  125  amide gel and autoradiography  of aliquots of  I-C3b-lgG (left)  and  I-C3b (right)  before 
(time 0), and at timed intervals during,  incubation with 1:50 NHS in PBS (pH 7.4) with 0.01 
M EDTA and 25 t~M NPGB. Standards indicated are ×I0  s. 
removed at time zero and after various time intervals and studied by SDS-PAGE 
and autoradiography.  A  typical autoradiogram is shown in Fig.  3. A  progressive 
diminution  in  both a'-heavy chain and a'  chain  was seen,  with the latter being 
cleaved  more  rapidly.  125I-C3b  a'  cleavage  gave  rise  to  a  fragment  with  a 
molecular weight of 43,000  (occasionally a  doublet)  and a  broad band with  an 
apparent  molecular weight of 60,000.  This latter band was distorted  by serum 
albumin,  for  when  SDS-PAGE  of the  cleavage  products  was  performed  after 
immunoprecipitation  with  anti-C3-Sepharose  and  washing away of serum  pro- 1646  RETARDED  INACTIVATION  OF  C3b  BOUND TO  lgG 
teins, this fragment was shown to have an apparent molecular weight of 69,000 
as previously reported by others (21).  125I-C3b-IgG 0~'  chain cleavage gave rise 
to a  more complex pattern (Fig.  3). As with  125I-C3b,  a  43,000  mol wt fragment 
was produced. Cleavage of c~'-heavy chain gave rise to a  major fragment migrat- 
ing just  above  or  merging  with  uncleaved  W-light  chain.  The  behavior of c~'- 
light chain was difficult to assess because of this co-migrating fragment, but could 
be inferred from the appearance of a  new fragment with an apparent molecular 
weight  of ~120,000.  Because  the  larger cleavage  fragments  of a'-heavy chain 
and  d-light  chain  behaved  as  somewhat  heavier  molecules  than  anticipated 
(150,000 vs.  124,000 and  120,000 vs. 94,000, respectively), we subjected serum- 
cleaved  ~251-C3b-IgG to  treatment  with  1  M  hydroxylamine and  1%  SDS,  pH 
11.0, for  15 rain at 37°C.  The fragments released were identical to the 69,000 
and 43,000 tool wt fragments derived from 125I-C3b (data not shown), suggesting 
that  cleavage proceeded at  the  same  site  in  free and  IgG-bound  C3b and  that 
the  120,000  tool wt  fragment arose from c~'-light chain,  not a  second cleavage 
of the  150,000 tool wt W-heavy chain fragment. 
The relative  rates  of inactivation  of C3b  in  the  free state  or  bound  to  IgG 
were examined by densitometric scanning  of autoradiograms  of kinetic experi- 
ments as described in Materials and Methods.  Fig. 4 depicts the cleavage kinetics 
of radiolabeled d-heavy chain and free ~'  chain in six experiments in which we 
used three separate preparations of 125I-C3b and 125I-C3b-IgG. Cleavage of lzsI- 
labeled d-heavy chain was uniformly retarded relative to that of ~z5I-labeled a' 
chain. A  statistically significant difference in the percentage of relevant ~' chain 
FIGURE 4.  Kinetics  of serum-mediated c~' chain and W-heavy chain cleavage. Cleavage of 
~25I-labeled a'  chain (open symbols) and  15I-labeled d-heavy chain (closed symbols) was 
followed by densitometric scanning of autoradiographs  of kinetic inactivation experiments 
(Fig. 3). Cleavage of both 125I-labeled  a' chain species was assessed by diminution relative to 
tile zero time point, which was assigned a value of 100%. Data shown represent mean values 
fi'om six experiments; shaded areas denote 95% confidence intervals for the experimentally 
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intact was apparent at every time point examined. The kinetics of a'-light chain 
cleavage were not readily evaluable because of interference by the 150,000 mol 
wt cleavage fragment of a'-heavy chain. 
Interaction of Factors H  and I with ~51-C3b and 125I-C3b-IgG.  Since the initial 
conversion of C3b  to  inactivated C3b  (iC3b)  is accomplished in  serum by the 
concerted action of factors H  and I, we reasoned that the interaction of one or 
both of these proteins with C3b may be altered when C3b is bound to IgG, thus 
producing a slowed rate of inactivation. To investigate this possibility, we studied 
the extent of cleavage of 125I-labeled  a'  chain and  125I-labeled  od-heavy chain 
under standardized conditions (30 min, 37°C, fixed factor I input) as functions 
of purified factor H  concentration in the reaction mixture. Factor H  concentra- 
tions of 0.715-174  #g/ml were studied in reaction systems containing 5-6 ~tg/ 
ml of ~2"~I-C3b residues. As shown in Fig. 5, the dose-response curve for a'-heavy 
chain cleavage was significantly displaced from that of free a'  chain. Over the 
majority  of the  range  studied,  approximately  threefold  more  factor  H  was 
required for equivalent a'-heavy chain cleavage when compared with a'  chain. 
These data suggested that binding to IgG significantly reduced the affinity of 
12"~I-C3b for factor H. To address the possibility that binding to IgG might also 
directly alter the interaction of C3b with factor I, two cubic polynomials describ- 
ing the central portions  of the curves in  Fig.  5  were derived using a  general 
polynomial least Squares curve-fitting program. With the use of these expressions, 
factor H inputs of 17.7 ug/ml for ~25I-C3b and 51.9 #g/mi for 12~I-C3b-IgG were 
chosen as giving equivalent cleavage of 38% of the relevant a' chain under the 
standard  conditions,  and  a  dose-response  experiment  was  performed over  a 
range of factor I dilutions. As shown in Fig. 6, the dose-response curves generated 
were virtually identical. These results lead us to conclude that, given sufficient 
100 
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FIGURE 6.  Cleavage of a' and a'-heavy chain as a  function of factor I  input.  ~tsI-C3b was 
mixed with 17.7 #g/ml of factor H and t~sI-C3b-lgG with 51.9 #g/ml factor H  on the basis of 
data in Fig. 5, and cleavage was allowed to proceed at 37°C for 30 min in the presence of a 
range of dilutions of partially purified factor 1.  Cleavage of 125I-labeled  a'  chain and  l~sI- 
labeled a'-heavy chains was assessed as described in Materials and Methods. 
factor H, the susceptibility to factor I activity was not intrinsically reduced for 
the IgG heavy chain-bound a' chain. 
Cleavage  of C3b Bound  to a Non-lgG  Glycoprotein.  At a  molecular weight of 
150,000-160,000,  IgG represents a bulky substituent when covalently linked to 
C3b.  We questioned whether similar retardation of factor H- and I-mediated 
inactivation might occur when any glycoprotein of similar size was bound to 
C3b. We chose ceruloplasmin to test this hypothesis on the basis of its significant 
carbohydrate content (8.4%), similarity to IgG in molecular weight (134,000 vs. 
150,000-160,000),  and ready availability in good purity in our laboratory. We 
prepared ~25I-C3b-ceruloplasmin by methods analogous to those used in prepar- 
ing  ~25I-C3b-IgG  and  enriched the  preparation  for the  hetero-dimer by  two 
sequential  sieve  chromatography steps.  As  shown  in  Fig.  7,  this  preparation 
contained ~38% of total and 54% of a' chain-associated radioactivity in a broad 
band with an apparent molecular weight of 265,000-270,000  on reduced SDS- 
PAGE. This band could be immunoadsorbed by anti-ceruioplasmin-Sepharose, 
and radioactivity was specifically precipitated by anti-ceruloplasmin antisera in 
double diffusion (Fig. 7, inset). The cleavage of 12~I-labeled a'-ceruloplasmin in 
serum was studied in a manner analogous to that used for a' chain and a'-heavy 
chain. As shown in Fig. 8, ~25I-C3b a' chain bound to ceruloplasmin was cleaved 
by serum factors H and I with kinetics indistinguishable from those of free ]25I- 
C3b  a'  chain  cleavage. These data suggested that  the size  of the substituent 
molecule bound to C3b may not be the sole determinant ofC3b a' chain cleavage 
rate, and are consistent with the hypothesis that binding to IgG may mediate an 
enhancement of C3b survival not common to all C3b acceptors. FRIES  ET  AL.  1649 
FIGURE 7.  ~5I-C3b-ceruloplasmin. The t~51-C3b-ceruloplasmin  pool was subjected to SDS- 
PAGE under reducing conditions in a 5% slab gel. After staining and drying, autoradiography 
was performed as described in Materials and Methods, followed by densitometric scanning. 
The abscissa  denotes the  internal scale  of gel-scanning apparatus and does not necessarily 
correspond to the absolute dimensions of the gel. The position of molecular weight marker 
proteins is noted above the scan profile. Inset demonstrates double diffusion analysis of ~251- 
C3b-ceruloplasmin in 1% agarose. An antigen mixture of 1~5I-C3b-ceruloplasmin  (~10 t~g/ml) 
with 100 #g/ml  each of unlabeled ceruloplasmin, C3b, and HSA, was placed in central wells 
(a). Antisera in surrounding wells included anti-C3 (b), anti-ceruloplasmin (c), and anti-HSA 
(d).  Note  that  1~5I (confined to  C3b)  was  precipitated  by anti-ceruloplasmin, but was  not 
significantly trapped nonspecifically by HSA-anti-HSA precipitin lines. 
FIGURE 8.  Kinetics of serum-mediated a ~ chain-ceruloplasmin cleavage. Cleavage of ~sI- 
labeled a' chain-ceruloplasmin by 1:50 serum was quantitated as previously described for a' 
chain and a'-heavy chain. Data shown represent means and standard errors for three experi- 
ments and are superimposed on shaded areas denoting the 95% confidence intervals for a' 
chain (lower  band) and a'-heavy chain (upper band) cleavage kinetics. 1650  RETARDED  INACTIVATION  OF  C3b  BOUND  TO  IgG 
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FIGURE 9.  Consumption  of C3  by C3b-lgG and C3b.  Varying amounts of 1~51-C3b, free 
(open symbols) or covalently bound to IgG (<_-10% free C3b, closed symbols), were added to 
1:25  mg/EGTA-NHS,  and the consumption of hemolytic C3  was assessed after  30  rain at 
37 ° C. Data shown represent means and standard errors from three experiments in which two 
different C3b-IgG preparations were used.  18.3% consumption at zero input represents the 
decline of C3 titer of 1:25 Mg/EGTA/NHS after 30 rain at 37°C in buffer alone (relative to 
an aliquot of 1:25 Mg/EGTA-NHS held on ice in 0.01 M EDTA for 30 rain). 
Consumption  of Serum C3 by C3b and C3b-IgG.  We next studied the capacity 
of free 125I-C3b and  125I-C3b-IgG  to mediate alternative pathway activation in 
serum. The two 125I-C3b species were diluted in VBS (pH 7.4) with 2 mM MgCI2 
and 40  mg/ml HSA, and the capacity of equal amounts of free or IgG-bound 
125I-C3b to mediate hemolytic C3 consumption from 1:25 Mg/EGTA-NHS was 
studied over a  range of 125I-C3b residue inputs.  As shown in Fig. 9, both C3b 
and C3b-IgG demonstrated a dose-dependent consumption of serum C3 activity. 
However, while free C3b  inputs of >20 #g/ml  were required for consistently 
observable consumption in excess of buffer controls, C3b-IgG produced signifi- 
cant consumption of C3 at inputs of 5 gg/ml. Markedly greater reductions in C3 
titer were caused by C3b-IgG, compared with C3b, at all concentrations tested. 
Centrifugation of 125I-C3b and ~25I-C3b-IgG at 178,000 g for 30 min to remove 
large aggregates failed to alter either consumption curve. 
Discussion 
Deposition of C3b at a site of complement activation is critical to the initiation 
of assembly of the late components (C5-C9) into the membrane-attack complex 
and also serves to engage the alternative, or amplification, pathway for further 
C3b production (21).  These activities are abrogated when C3b is inactivated to 
form  iC3b.  In  addition,  C3b  mediates  attachment  to  specific  receptors  on 
phagocytic cells and primate erythrocytes (22). C3b dramatically enhances IgG- 
mediated phagocytosis of opsonized particles and, under appropriate circumstan- 
ces, can itself precipitate phagocytosis (23). Inactivated C3b functions in some of 
these roles, but may not be equivalent to C3b in all cases (24). 
The  survival of C3b  in  an active  state  on  an  immune complex, soluble  or 
particulate, may therefore be of considerable importance in determining the fate FRIES  ET  AL.  1651 
of the complex. As we have previously noted, a variety of evidence suggests that 
C3b  may exhibit altered behavior when bound to IgG.  One interpretation of 
such evidence is that binding to IgG prolongs survival of C3b in the presence of 
the various control proteins, and the current experi/nents were undertaken to 
examine this possibility. Classically, C3b is inactivated in serum by the concerted 
action  of factors  H  and  I  (25).  More  recently (14,  26),  the  role  of the C3b 
receptor (CRy) as a cofactor for factor I has been appreciated. While CR~  may 
be central to the handling of large but soluble immune complexes in the blood, 
its role in C3b inactivation outside the bloodstream or on particulate complexes 
remains to  be defined.  Further, since CR~  exhibits very low affinity for C3b 
monomer at normal ionic strength, the interaction of this receptor with com- 
plexes bearing only one C3b residue, or a low density of such residues, would be 
limited (3). Accordingly, we chose the well-characterized factor H  and I system 
for our initial investigations of C3b-IgG inactivation. 
In agreement with several previous reports (3, 27), we found monomeric IgG 
to be a ready acceptor of nascent C3b. C3b appeared capable of binding to both 
light  and  heavy  chains  of IgG,  although  heavy  chain  was  the  predominant 
acceptor, accounting for an average of 76%  of bound a'  chain.  This  finding 
agrees well  with  existing data  from a  variety of experimental systems (4,  5), 
wherein the major C3b  acceptor site  in  IgG has been  found to  reside in  the 
heavy chain  and  probably  the  Fd  fragment.  Light  chain  uptake  of C3b  has 
previously been reported by Brown et al. (6), who used a classical pathway system 
on  bacteria, and by Arnaout and colleagues (3),  who used trypsin cleavage of 
C3,  whereas several other investigators (4,  5) have not noted such uptake in 
systems examining alternative pathway activation by model immune complexes. 
In our studies,  virtually all  bound a'  chain was removed from both  light and 
heavy chains of IgG by hydroxylamine treatment.  This  finding is at  variance 
with those of Gadd and Reid (4) and Brown et al. (6), who found hydroxylamine 
sensitivities of 26 and 66%, respectively. More recently (5), however, Takata et 
al. have shown complete hydroxylamine release of C3b deposited via the alter- 
native pathway on  model immune complexes containing either intact  IgG or 
F(ab')2 fragments. They postulated that C3b may bind to IgG via an ester linkage 
to hydroxyl-bearing amino acids. This hypothesis is compatible with the findings 
reported here. The relative prevalence of ester and amide linkages, as well as 
the extent of light chain uptake of C3b, is probably a function of the mechanism 
of C3 activation and the state of the accepting IgG. It is reasonable to conclude, 
however, that C3b  linked to a  site within the heavy chain of IgG via an ester 
bond represents the major C3b-IgG species in  most systems thus far reported 
(3-6). The cleavage of od-heavy chain complexes that arise from such linkage is 
the subject of our kinetic data. 
We observed that the a' chain of C3b is cleaved by serum factors H and I into 
fragments with molecular weights of 69,000  and 43,000,  as has been demon- 
strated  in  a  previous  report  (21).  The  lower molecular weight fragment fre- 
quently appeared as a  43,000  and 46,000  doublet, probably reflecting partial 
release of the 3,000  mol wt fragment C3f (21).  The products of C3b-IgG a' 
chain cleavage included the same 43,000-46,000  mol wt fragments, as well as a 
major band of 150,000 and a minor band of 120,000. Hydroxylamine treatment 1652  RETARDED  INACTIVATION  OF  C3b  BOUND  TO  IgG 
released a typical 69,000  mol wt a' chain fragment from both of these species, 
suggesting that they arise separately and not sequentially, and thus represent the 
products of a'-heavy chain and a'-Iight chain cleavage. The unexpectedly high 
apparent molecular weights of these C3b-IgG fragments presumably represents 
anomalous behaviour in SDS-PAGE; similar results have been reported by Takata 
et al. (5). 
A consistent retardation of factor H- and I-mediated cleavage of heavy chain- 
linked C3b a' chain, relative to free C3b a' chain, was noted. The same extent 
of retardation  was  noted  in  C3b-IgG  preparations  containing  from  5-30% 
contamination  with  free  C3b,  and  thus  is  unlikely  to  represent  competitive 
inhibition  by  free C3b.  Additionally, in  factor H  dose-response experiments, 
large differences in the extent of a'  and a'-heavy chain cleavage were readily 
observable even when the latter was exposed to factor H inputs >10-fold greater 
than total  combined a'  and a'-heavy chain input.  Such dose-response experi- 
ments demonstrated that retarded inactivation of C3b-IgG is an exclusive result 
of diminished affinity of C3b-IgG for factor H. There was little or no observable 
alteration in the shape of the factor I dose-response curve for C3b-IgG inactiva- 
tion relative to free C3b, provided that a sufficient level of factor H was supplied. 
This finding is similar to previous observations (28) which suggest that the major 
determinant  of impaired  C3b  inactivation  on  alternative  pathway-activating 
surfaces is reduced affinity for factor H. 
The mechanism by which IgG interferes with the interaction of factor H  and 
C3b is unclear. The simplest possibility would be a direct steric hindrance based 
on the size of the IgG molecule closely applied to C3b.  Our experiments with 
~25I-C3b-ceruioplasmin hetero-dimers demonstrated, however, that a  glycopro- 
tein similar in size to IgG could be bound to C3b with little apparent effect on 
the rate of serum-mediated o~' chain cleavage. Additionally, in preliminary studies 
of the cleavage of low densities of C3b residues on sheep erythrocytes by  1:50 
NHS at normal ionic strength,  using the method of Gaither (17),  we demon- 
strated kinetics quite similar to those we observed with fluid phase C3b. Taken 
together, these findings suggest that binding to IgG may render C3b relatively 
less susceptible to the action of factors H  and I in a manner not common to all 
potential  acceptors.  It  is possible  to  speculate that  the portion(s) of IgG  that 
mediate  noncovalent  binding  to  C3  and  C3b  (2)  also  provide  a  protective 
microenvironment for the covalently bound species. Alternatively, the relatively 
low sialic acid content of IgG compared with ceruloplasmin (and the majority of 
other human glycoproteins) may mediate protection of C3b by an as yet unde- 
fined mechanism (28). 
C3b-IgG appears to be much more effective, on a molecule-for-molecule  basis, 
than free C3b in mediating alternative pathway consumption of serum C3. This 
finding not only reinforces our observations regarding the resistance of C3b-IgG 
to inactivation, but suggests that  IgG does not significantly interfere with the 
binding of factor B to C3b.  In this manner also, C3b-IgG behaves similarly to 
C3b bound to an alternative pathway-activating surface (28). 
The mechanism by which IgG exerts its effects on alternative pathway activa- 
tion  has not  been  delineated.  Our  data suggest that  C3b  which is  covalently 
bound to IgG, even in small hetero-dimeric forms, demonstrates retarded inac- FRIES  ET  AL.  1653 
tivation by factors H and I and behaves similarly to C3b bound to an alternative 
pathway-activating surface.  Thus,  it  is possible to speculate that  IgG confers 
alternative pathway-activating potential on nonactivating surfaces by providing 
a protected site for C3b deposition. On alternative pathway activators, IgG might 
act  synergistically  to  further  depress  the  action  of  the  control  proteins  on 
deposited C3b.  C3b covalently linked to IgG could, by virtue of its enhanced 
survival, participate more effectively in both C3 and C5 convertases with resultant 
increased C3b deposition and enhanced initiation of membrane-attack complex 
formation. Data suggesting the operation of both of these mechanisms have been 
obtained in bacterial killing and erythrocyte iysis systems (8-13). In addition, the 
long-lived C3b-IgG complex might be a potent signal for ingestion by phagocytic 
cells, since it presents closely linked ligands for two opsonically active cell surface 
receptors. In the case of C3b-bearing soluble immune complexes, our data may 
in part explain the observations of Medoff (14) demonstrating that erythrocyte 
CR~ is required to support factor I inactivation of complex-bound C3b, although 
additional mechanisms must be operative to explain the apparent total insuscep- 
tibility of such C3b to factors H  and I. Recent work by Jacobs and Reichlin (7) 
suggests that C3b-IgG hetero-dimers are formed from "innocent bystander" IgG 
in serum during complement activation. Since these small hetero-dimers would 
be expected to bind poorly, if at all, to CR~ at normal ionic strength (3), retarded 
inactivation  by  factors  H  and  I  might contribute  to prolonged circulation  of 
these complexes as C3b-IgG, with as yet unpredictable effects on phagocytic cell 
receptors and, perhaps, immunoregulatory functions. 
Summary 
We have prepared C3b covalently linked to IgG via a hydroxylamine-sensitive 
bond between  the C3b or'  chain and sites predominantly, but not exclusively, 
located in the IgG heavy chain. This C3b species displays relative resistance to 
inactivation by factors H  and I  when compared with free C3b. This resistance 
appears to be due entirely to reduced affinity of C3b-IgG for factor H. Resistance 
to inactivation is not conferred on C3b by binding to another serum glycoprotein 
of similar size, ceruloplasmin, and may be a  special property of IgG.  C3b-IgG 
demonstrates an enhanced capacity to consume serum C3 relative to C3b. These 
alterations of the behavior of C3b when bound to IgG may in part explain the 
augmentation of alternative pathway activity by IgG. In addition, IgG-induced 
protection of C3b might influence both complement-mediated killing and phag- 
ocytosis of bacteria,  as well as  modify the in vivo handling of IgG-containing 
soluble immune complexes. 
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